



GATC Health

REG A INVESTOR OVERVIEW

DISCLAIMER

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY'S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS "ESTIMATE," "PROJECT," "BELIEVE," "ANTICIPATE," "INTEND," "EXPECT" AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT'S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY'S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. YOU MAY OBTAIN A COPY OF THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM:

<https://www.manhattanstreetcapital.com/offering-circular/27033>

YOU SHOULD READ THE OFFERING CIRCULAR BEFORE MAKING ANY INVESTMENT.



GATC HEALTH

Discovering the Shortest Path to Better Drugs

We believe GATC Health's advanced AI platform creates safer, more effective therapeutics in record time.

GATC Health works to accelerate, optimize and de-risk drug discovery and development—creating tremendous value for our partners and customers. Our advanced technology closes the "AI Gap," potentially saving years of R&D time and hundreds of millions of dollars per project.





GATC Health's proprietary AI simulates individual human biology to:

These breakthroughs are possible with GATC Health's patented platform, which functionally acts like a digital humanoid. Drawing on large sets of public and proprietary multiomic data, our AI simulates human biology's billions of interactions which, we believe, leads to the following: (i) rapid and accurate target discovery, (ii) drug identification, (iii) development and (iv) validation of safety and efficacy.



Discover new drugs or repurpose existing drugs in record time



De-risk drug development and clinical trials



Assess individual health risks



Recommend the best treatment options

We Have A Strong Management Team With A Proven Track Record Of Success

GATC Health Management



John Stroh, Chief Executive Officer

- 30+ years in investment-banking specializing in health care
- Served in various C-level rolls with biotech companies



Jeff Moses, President

- Former CMO of PowerOne Energy Corp
- Multiple C-level positions with growth stage companies
- Founder & creative director of ad agency serving Fortune 500 clients



Kevin Woodbridge, Executive Vice President

- 30+ years in finance and corporate development
- Lead \$100M+ financing for various companies



V. Tyrone Lam, Chief Operating Officer

- Co-founder & COO, First Americans Wellness
- Co-founder, OneRecovery & OneHealth Solutions (purchase by Viverae/SimplyWell)
- VP Business Development, Predilytics (purchased by Welltok)
- President & COO, NTN Buzztime



Ian Jenkins, Chief Science Officer/Cofounder

- Founder & CEO, Frélii, Inc.
- Marketing & Product Development, Systemic Formulas
- Dietary Supplement Designer, Next Supplements
- Researcher, Human Genome Project
- Junior VP & Clinical Development, ORN Industries



Jayson Uffens, Chief Technology Officer

- Founder & CEO, IrisMind
- Engineering VP, GrubHub
- Head of Engineering, Seamless
- Engineering Manager & Architect, Northrop Grumman Information Systems



Preetaman Wadhwa, Chief Marketing Officer

- Global Market Lead, Amgen
- Marketing Director, Cardiology, Amgen
- Masters in Health Systems Management, MBA, B.S. Pharmacy



Chad Penry, Director of Business Development

- Founder, Quan Financial - business consulting & strategic partnerships
- Strategic partnerships with Fortune 500 companies, leading industry professionals, celebrities, artists, athletes, and non-profit organizations.

Industry Leading Science and Business Advisors

Scientific Advisors



Dr. Jonathan Lakey, Chair of Scientific Advisory Board

- Professor Emeritus, Surgery & Biomedical Engineering, UC Irvine School of Medicine
- International Speaker, islet transplantation, stem cell research and diabetes
- 500+ authored scientific papers



Eric J. Mathur, Science Advisor

- TLIT Holdings, Yulex Corporation, Synthetic Genomics, Diversa Corporation
- Strategic Advisor, Health & Wellness; Pegasus Capital Advisors, NY
- Internationally recognized expert in genome sciences, molecular biology, microbiology & plant molecular breeding
- Named inventor on >150 patents; 50+ peer reviewed publications with >8,000 citations



Dr. Jack Lewin, Science Advisor

- Chairman, National Coalition on Health Care, Washington DC
- Former CEO, American College of Cardiology
- Former President & CEO of Cardiovascular Research Foundation
- Former CEO, California Medical Association




Dr. Stanley Lewis, Science Advisor

- Co-founder & CEO, A28 Therapeutics
- Former Chief Medical Officer, Ansun Biopharma
- Former Chief Medical Officer, TaliMed Biologics
- Director of Drug Development, Tanox



Dr. Chitra Bhakta, Science Advisor

- Chronic disease specialist
- Physician at OC Integrative Medical Center



Dr. Negar Motoyagheni, Science Advisor

- Anesthesiology and Intensive Care TUMS/SBU, Scientist UCLA
- Regenerative Medicine Fellowship WFIRM
- 20+ academic certificates



Dr. David Kushner, Science Advisor

- 35+ years as Nuclear Radiology Specialist / US Navy Physician
- Fellow in Musculoskeletal imaging and Nuclear Medicine
- Assistant professor at Uniform University of the Health Science

Business Advisors



Steve Lebedoff, Business Advisory Board Member

- SVP, Aon Risk Consulting (Consulting to Fortune 500 Companies)
- Executive Officer, PPN Health Access
- Co-founder, Center for Sustainable Healthcare, University of Nevada



Jim Arellano, Business Advisory Board Member

- President and Founder BP Insurance
- Former VP of National Accounts, United Health Group
- 35+ years' experience in Healthcare Industry



Darius Naigamwalla, Business Advisory Board Member

- Executive Vice President, Two Labs Pharmaceutical
- Former CEO, CEEK Enterprises: BioPharma Consulting
- Former President, Campbell Alliance (now Syneos Health)
- 20+ years in BioPharma consulting & commercialization



LTC (R) Wade Jost, Military + Federal Advisor

- CEO, 640 Areas (Service-Disabled Veteran Owned Small Business)
- U.S Army's Rapid Equipping Forces (REF)
- Office of Secretary of Defense Joint IED Defeat organization
- U.S Military Academy of West Point



Pharmaceutical R&D: Bridging the AI Gap for Drug Discovery

To our knowledge, GATC Health is the first company to bridge the AI Gap. But what is the AI Gap?

Traditionally, drug companies make assumptions about a disease and possible drug candidate molecules. This creates a giant haystack of data. They spend hundreds of millions of research dollars—and many years—analyzing each strand of “hay” trying to find the needle, or exact drug candidate.

Our competitors use AI to reduce the size of the haystack. At their best, they can reduce the haystack from 10,000 or more possible targets down to approximately 1,000. This can save several years and considerable expense—but it is only an enhancement to the traditional model.

The AI Gap is the difference between what our competitors deliver—a smaller haystack—and what GATC Health’s patented platform can deliver: the exact needle.



Personalized Medicine: Genetics-Based Diagnostic Tools for Consumers



Creating new drugs starts with gathering data. Instead of paying for valuable biological data, GATC Health created a model for early disease detection and treatment optimization where customers pay us to collect their data. In turn, GATC provides a personalized, actionable report illustrating disease risk and recommended treatment options.

The company intends to complete the following diagnostic tools over the next 12 months:

- Diabetes
- Cardiac Health
- Alzheimer's
- Parkinson's
- PTSD



With a single cheek swab, our proprietary DNA test kits can identify your precise risks and recommended treatment for

- Viral Immunity
- Depression & Anxiety
- Medical Cannabis
- Health & Wellness



GATC Health licenses these proprietary multiomic diagnostic tests to companies that distribute the products to consumers and physicians, enabling precision and predictive medicine across clinical settings.





New Drug Candidates in Months, Not Years

Via our relationship with Liquid Biosciences, world-class biomarker discovery company, GATC technology has created a new drug discovery platform. In our first project with Liquid Biosciences, GATC has:

- Validated biomarkers for addiction
- Discovered a new molecule for addiction treatment
- We completed this work in a record breaking 9 months
- Internal estimates of 50% or more reduction in drug discovery timeline
- Net present value increase of over \$500 million per drug, due to risk reduction, cost reduction and acceleration
- Co-developed an AI-driven pipeline for new drug discovery, which has already produced multiple breakthrough molecules

Liquid Biosciences has completed over 192 projects with major pharmaceutical firms and research organizations for biomarker discovery, diagnostics, drug discovery, drug repurposing, database services, and analytics



Who Benefits from GATC Health's Technology?

In short: everyone.



PHARMACEUTICAL COMPANIES

Our tech enables faster and more accurate drug discovery, drug repurposing and drug development. We de-risk and improve value through pre-clinical in silico and in vivo testing, prescreening clinical trial participants and validating clinical trial data.



INDIVIDUALS

Patients can now access fast and affordable personalized DNA analysis of disease risk, tolerance, complications, and prevention through our distribution partners. Drugs discovered by GATC Health will be safer and more effective because they are better targeted to each disease.



DOCTORS

With individualized multiomic data for their patients, clinicians can provide cutting-edge, ultra-efficient medical care for better health outcomes.



The Impact of AI

Mark Cuban, one of the most innovative and respected Internet-based entrepreneurs of our time, recently stated that artificial intelligence, *“...will have a bigger impact on us than the Internet, than phones, mobile computing, mobile networking, wide-area networking—it’s just going to dwarf everything.”* He went on to point out that, *“...it’s harder to learn, harder to implement, and not everyone is going to be able to adapt...we are still in the first innings of the preseason game.”*

As one of the richest people in the world, Bill Gates is known for contributing to global health through the Gates Foundation. As his biggest legacy, Microsoft is also moving in the same direction. The company is actively involved in helping the world’s population overcome some of the most challenging health problems and concerns.

Microsoft recently announced a new healthcare initiative known as “AI for Health,” a program worth over 40 million dollars. AI for Health evolved out of the AI for Good Program, which offers general aid to the less fortunate around the world.



A female scientist with blonde hair tied back, wearing a white lab coat over a light blue shirt, is looking through a blue and white microscope. The background is a blurred laboratory with shelves and equipment. The text is overlaid on the right side of the image.

Market Opportunity

GATC Health sits at the center of four growing markets: genetic testing, AI in healthcare, personalized medicine and the world longevity economy.



Artificial Intelligence in Healthcare: \$120 billion by 2028



AI is the future of medicine, and GATC Health's MAT platform is a leader in AI's potential, and we believe outperforms competitors in comprehensive analysis, industry-specific AI training, and flexibility of application.

The global market for AI in healthcare size was estimated at \$6.7 billion in 2020 and is expected to reach USD 10.4 billion in 2021 with a global CAGR rate 41.8% from 2021-2028, hitting \$120.2 billion by 2028.⁵



Personalized & Precision Medicine: \$493 billion and growing



With the proliferation of affordable genetic testing and a growing clinical interest in pivoting from generalized, one-size-fits-all, and reactive medicine, GATC Health's proprietary genome test kits will be at the forefront of the explosive precision medicine market. As our tech empowers predictive and personalized healthcare that facilitates better research and patient outcomes, we anticipate a positive feedback loop of interest and widespread applicability of our tech.

World Longevity Economy: \$27 trillion in the next 5 years

Longevity research will accelerate important medical breakthroughs benefitting all humans, enabling longer and healthier lives. This opens the possibility to potentially turn longevity into an asset. Businesses who are able to tap this aging consumer market, such as GATC Health, are poised to stay ahead of the curve.

Globally, the longevity economy is responsible for \$7.6 trillion in economic activity, with no signs of slowing down. In fact, the economic impact of the longevity economy is projected to triple by 2050.⁶



GATC Health's Competitive Advantage

As Genomics/AI companies continue to fetch huge valuations, GATC Health is uniquely positioned to flourish in these new economies. Our proprietary MAT AI/genomics platform and Predictive Multiomics database are proven to deliver groundbreaking results across a variety of lucrative applications advancing human health and scientific progress.



Biological Context

- MAT AI provides superior biological context to omics data with the faster processing speed and scalability preferred by major industry partners.

Faster Processing Speed

- The opportunity is immense. GATC's technology can be taught to address nearly any condition, disease or disorder.

Scalability

- Our Predictive Multiomics database and MAT AI make us a complementary technology to others in this space. Companies that may have been competitors can now utilize our technology as partners.



Quotes from Advisors



Dr. Stanley Lewis

"I am excited to work with GATC's team to identify and provide actionable data that benefits both patients and providers of care. GATC technology is perfectly aligned to provide the kind of relevant reports that give physicians and caregivers the information they need to optimize care plans."



Dr. Jack Lewin

"GATC's mission to find earlier detection, prevention and treatment across the disease spectrum is backed by their talent and technology."



Dr. Jonathan Lakey

"GATC Health has presented me with an incredible opportunity to make significant advancements in the detection and treatment of diabetes. I have been tasked with assembling a world-class team of scientific and technical experts to further develop a diabetes-focused platform utilizing the company's Multiomics Advanced Technology™ (MAT). The GATC Health diabetes platform has the potential to revolutionize the way we detect diabetes before it develops in an individual and possibly arrest its progression through new treatments and transplantation protocols."



GATC HEALTH

GATC Health Investment Offering

Type:

Reg A + offering

Price:

\$5.00 per share of Common Stock

\$250,000,000 market cap (approximately 50 million shares fully diluted)

As the industry continues to push for expedited solutions for Emergency Use Authorizations, drug discovery, biomarker discovery, precision medicine, and more, GATC Health will continue to lead and innovate.

It's an exciting time to be in biotech.

As a GATC Health investor, you're in the perfect place at the perfect time. Will you step into the future with us?



Thank You

Please contact your investor relations representative for more information

833.333.GATC (4282)
info@gatchealth.com

GATC Health Corp
2030 Main Street, Suite 660
Irvine, CA 92614



GATC Health